ArticleMolecules (Basel, Switzerland)2020
Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.
Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 78 citations in OpenAlex.
- In Vitro Assessment of the Combined Activity of Amphotericin B and CuTropical medicine and infectious disease · 2025Article
- Nanofibrous patches for targeted therapy of cutaneous leishmaniasis caused by Leishmania major: a preclinical amphotericin B platform.Parasitology research · 2025Article
- Enhanced Skin Delivery of Amphotericin B: Development and Evaluation of Polymeric Nanoparticles Using a Porcine Ear Model.ACS omega · 2025Article
- In vitro and in vivo evaluation of the leishmanicidal and cytotoxic activities of chitosan and chitosan-amphotericin B.AMB Express · 2025Article
- Article
- Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis.Vaccines · 2024Review
- Chitosan nanoparticles improve the effectivity of miltefosine against Acanthamoeba.PLoS neglected tropical diseases · 2024Article
- Development of solid lipid nanoparticles-loaded drugs in parasitic diseases.Discover nano · 2024Review
- From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease.International journal of molecular sciences · 2023Review
- Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas Disease.Pathogens (Basel, Switzerland) · 2023Review
- Metallic Nanoparticles and Core-Shell Nanosystems in the Treatment, Diagnosis, and Prevention of Parasitic Diseases.Pathogens (Basel, Switzerland) · 2023Review
- Chitosan: A Potential Biopolymer in Drug Delivery and Biomedical Applications.Pharmaceutics · 2023Review
- Polymeric Nanoparticles as Tunable Nanocarriers for Targeted Delivery of Drugs to Skin Tissues for Treatment of Topical Skin Diseases.Pharmaceutics · 2023Review
- Amphotericin B- and Levofloxacin-Loaded Chitosan Films for Potential Use in Antimicrobial Wound Dressings: Analytical Method Development and Its Application.Pharmaceutics · 2022Article
- In vitro efficacy of polymer coated miltefosine drug against leishmania tropica.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022Article
- Mechanism and Application of Chitosan and Its Derivatives in Promoting Permeation in Transdermal Drug Delivery Systems: A Review.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Dermal Absorption of Sesquiterpene Lactones from Arnica Tincture.Pharmaceutics · 2022Article
- Leishmaniasis and Chagas disease: Is there hope in nanotechnology to fight neglected tropical diseases?Frontiers in cellular and infection microbiology · 2022Review
- Chitosan-Based Nanomaterials as Valuable Sources of Anti-Leishmanial Agents: A Systematic Review.Nanomaterials (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chitosan nanoparticles have gained attention as drug delivery systems (DDS) in the medical field as they are both biodegradable and biocompatible with reported antimicrobial and anti-leishmanial activities. We investigated the application of chitosan nanoparticles as a DDS for the treatment of cutaneous leishmaniasis (CL) by preparing two types of chitosan nanoparticles: positively charged with tripolyphosphate sodium (TPP) and negatively charged with dextran sulphate. Amphotericin B (AmB) was incorporated into these nanoparticles. Both types of AmB-loaded nanoparticles demonstrated in vitro activity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.